Literature DB >> 20561594

Pretransplantation C-Peptide level predicts early posttransplantation diabetes mellitus and has an impact on survival after allogeneic stem cell transplantation.

Michelle L Griffith1, Madan H Jagasia, Amanda A Misfeldt, Heidi Chen, Brian G Engelhardt, Adetola Kassim, Bipin N Savani, Margaret Survant, Shubhada M Jagasia.   

Abstract

Posttransplantation diabetes mellitus (PTDM) is a frequent complication after allogeneic stem cell transplantation (allo-SCT), important for its negative impact on cardiovascular health. Risk factors for PTDM are not well defined. We conducted a prospective study to investigate the risk factors and incidence for PTDM in the first 100 days after allo-SCT. A total of 84 patients completed the study, 60% of whom developed PTDM. In a multivariate logistic regression model, pretransplantation c-peptide level (>3.6 ng/mL; odds ratio [OR], 5.9; 95% confidence interval [CI], 1.77-20.22; P = .004), unrelated donor allo-SCT (OR, 4.3; 95% CI, 1.34-14.2; P = .014), and peak steroid dose >1 mg/kg/day (OR, 5.09; 95% CI, 1.19-23.2; P = .035) were identified as independent predictors of PTDM. In addition, overall survival (OS) was inferior in patients with PTDM compared with those without PTDM (mean survival, 2.26 years vs 2.7 years; P = .021). Pretransplantation c-peptide level greater than the cohort median (>3.6 ng/mL) also was associated with inferior OS (mean, 1.7 years vs 2.9 years; P = .012). In a multivariate Cox proportional hazards model, high-risk disease (hazard ratio [HR], 2.34; 95% CI, 1.09-5.28; P = .029) and pretransplantation c-peptide level >3.6 ng/mL (HR, 1.05; 95% CI, 1.01-1.09; P = .013) were independent predictors of OS when adjusted for systemic steroids and regimen intensity. We suspect that diabetes mellitus in the immediate posttransplantation period may be mediated via an inflammatory pathway that contributes to insulin resistance in the host adipose tissue. Our study is the first to report the risk factors of early PTDM in patients undergoing allo-SCT and identifies pretransplantation c-peptide as an independent predictor of diabetes and survival. 2011 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20561594     DOI: 10.1016/j.bbmt.2010.06.010

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  7 in total

1.  Predicting posttransplantation diabetes mellitus by regulatory T-cell phenotype: implications for metabolic intervention to modulate alloreactivity.

Authors:  Brian G Engelhardt; Shubhada M Jagasia; James E Crowe; Michelle L Griffith; Bipin N Savani; Adetola A Kassim; Pengcheng Lu; Jörn-Hendrik Weitkamp; Daniel J Moore; Sandra M Yoder; Michael T Rock; Madan Jagasia
Journal:  Blood       Date:  2012-01-19       Impact factor: 22.113

2.  New-Onset Post-Transplant Diabetes Mellitus after Allogeneic Hematopoietic Cell Transplant Is Initiated by Insulin Resistance, Not Immunosuppressive Medications.

Authors:  Brian G Engelhardt; Ujjawal Savani; Dae Kwang Jung; Alvin C Powers; Madan Jagasia; Heidi Chen; Jason J Winnick; Robyn A Tamboli; James E Crowe; Naji N Abumrad
Journal:  Biol Blood Marrow Transplant       Date:  2019-02-07       Impact factor: 5.742

Review 3.  How do I manage hyperglycemia/post-transplant diabetes mellitus after allogeneic HSCT.

Authors:  S Fuji; A Rovó; K Ohashi; M Griffith; H Einsele; M Kapp; M Mohty; N S Majhail; B G Engelhardt; A Tichelli; B N Savani
Journal:  Bone Marrow Transplant       Date:  2016-04-04       Impact factor: 5.483

4.  Metabolic Complications Precede Alloreactivity and Are Characterized by Changes in Suppression of Tumorigenicity 2 Signaling.

Authors:  Romany A N Johnpulle; Sophie Paczesny; Dae Kwang Jung; Etienne Daguindau; Madan H Jagasia; Bipin N Savani; Wichai Chinratanalab; Robert F Cornell; Stacey Goodman; John P Greer; Adetola A Kassim; Salyka Sengsayadeth; Michael T Byrne; Brian G Engelhardt
Journal:  Biol Blood Marrow Transplant       Date:  2016-12-21       Impact factor: 5.742

5.  Soluble Suppression of Tumorigenicity 2 is Directly Correlated with Glycated Hemoglobin in Individuals with an Average glycemia in the Normal/Prediabetes Range.

Authors:  Amal Hasan; Waleed Aldhahi
Journal:  Diabetes Metab Syndr Obes       Date:  2020-08-03       Impact factor: 3.168

6.  Early high plasma ST2, the decoy IL-33 receptor, in children undergoing hematopoietic cell transplantation is associated with the development of post-transplant diabetes mellitus.

Authors:  Courtney M Rowan; Alicia M Teagarden; Daniel T Cater; Elizabeth A S Moser; Giorgos Baykoyannis; Sophie Paczesny
Journal:  Haematologica       Date:  2019-08-29       Impact factor: 9.941

7.  New-onset post-transplant diabetes mellitus after haploidentical hematopoietic cell transplant with post-transplant cyclophosphamide.

Authors:  Brendan L Mangan; Dilan Patel; Heidi Chen; Katie S Gatwood; Michael T Byrne; Salyka Sengsayadeth; Stacey Goodman; Bhagirathbhai Dholaria; Adetola A Kassim; Madan Jagasia; Wichai Chinratanalab; Kathryn A Culos; Brian G Engelhardt
Journal:  EJHaem       Date:  2020-09-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.